View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 23, 2018

MIT team develops single-injection polymer vaccine for polio

Researchers at the Massachusetts Institute of Technology (MIT) in the US have developed a new single-injection vaccine that can carry several doses in nanoparticles.

Researchers at the Massachusetts Institute of Technology (MIT) in the US have developed a new single-injection vaccine that can carry several doses in nanoparticles.

Intended to facilitate easy immunisation, the new product encapsulates inactivated polio vaccine in a biodegradable polymer called PLGA, which can degrade after a certain timeframe.

These polymer microspheres allow the release of the vaccine in two different bursts. The researchers used positively charged polymers in order to prevent the effect of byproducts, glycolic acid and lactic acid on the virus.

“These polymers are already approved by the US Food and Drug Administration (FDA) for in-human use.”

MIT former postdoc Stephany Tzeng said: “There’s always a little bit of vaccine that’s left on the surface or very close to the surface of the particle, and as soon as we put it in the body, whatever is at the surface can just diffuse away. That’s the initial burst.

“Then the particles sit at the injection site and over time, as the polymer degrades, they release the vaccine in bursts at defined time points, based on the degradation rate of the polymer.”

In order to test the single-injection vaccine, the MIT team designed nanoparticles to deliver an initial burst virus at the time of injection and another after approximately 25 days later, and injected them into rats.

Upon analysis at the Centers for Disease Control, blood samples from the immunised rats revealed that antibody response with the new vaccine was as strong as or stronger when compared to two injections of the Salk polio vaccine.

The researchers said that they could also design and combine particles that can release one dose at injection and a second one after two months, with those releasing vaccine at injection and one month later.

These polymers are already approved by the US Food and Drug Administration (FDA) for in-human use, and the team is planning to evaluate the vaccines in clinical trials.

The researchers are also in the process of employing the technique to devise stable single-injection vaccines for other viruses, including Ebola and HIV.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU